ClinicalTrials.gg
CompletedNCT00096785Updated Aug 10, 2010Results posted

Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection

A Phase 3 interventional study of entecavir and adefovir in Hepatitis B and Chronic Disease, sponsored by Bristol-Myers Squibb. Completed at 24 sites in 8 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2010-08-10.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's title name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Enrollment
41st of 61
69 · median 109
Started
2004
with 1 other
Phase 3
13 of 64
none open now
Registered
4th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 41st largest by enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2004, is one of 13 in phase 3, and was the 4th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate antiviral activity and efficacy of entecavir (ETV) compared to adefovir in adults with chronic hepatitis B who have not been treated yet with an antiviral medicine.

03

Conditions studied

  • Hepatitis B
  • Chronic Disease

Browse trials for

Keywords

  • chronic hepatitis B infection
04

In context

Hepatitis B, Chronic Reclassified

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's enrollment of 69 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Chronic treatment naive
  • Compensated liver disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Active comparator
    A1

    Drug: entecavir

  • Active comparator
    A2

    Drug: adefovir

Interventions

  • Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks

    Also known as: Baraclude

  • Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12

    Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 12, adjusted for baseline (Week 12 - baseline). A negative value = improvement.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in HBV DNA by PCR Assay at Week 48

    Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 48, adjusted for baseline (Week 48 - Baseline). A negative value = improvement.

    Time frame: Baseline, Week 48

  2. Viral Load Undetectable (HBV DNA <300 Copies/mL)

    Number of Subjects with HBV DNA \<300 copies/mL by Roche COBAS® Amplicor (limit of quantitation 300 copies/mL)

    Time frame: Week 48

  3. Alanine Aminotransferase (ALT) Normalization

    Number of participants with ALT ≤ 1 x upper limit of normal (ULN)

    Time frame: Week 48

  4. HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections

    The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε) and effectiveness of the study treatment in blocking de novo infection of susceptible cells (η). The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.

    Time frame: Week 12

  5. HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate

    The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the clearance rate of the free virus (c), the death rate of productively infected cells (δ), The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.

    Time frame: Week 12

  6. HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus

    The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. An important derived parameter is the half-life of free virus (ie, the average amount of time for HBV particles in plasma to be reduced to half the initial level), calculated as 24\*ln(2)/c. The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.

    Time frame: Week 12

  7. HBV DNA Viral Kinetics - Spline Model

    This analysis uses a 3-parameter piece-wise linear model and describes the biphasic decline in HBV DNA (measured by PCR assay) through Week 12. The 3 parameters are the values for the 2 slopes, describing the first and second phase declines, respectively, and the estimated HBV DNA at the knot (at day 10; the time point where the 2 phases join). The biphasic viral decay kinetics for each treatment were obtained using a spline fitting procedure to estimate the 3 parameters for each subject; these estimates were then averaged within each treatment group.

    Time frame: Week 12

  8. Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths

    AE=new untoward medical occurrence or worsening of pre-existing medical condition regardless of causal relationship to treatment. SAE=untoward medical occurrence that is life-threatening, a congenital anomaly/birth defect, or an important medical event, or results in death, inpatient hospitalization/prolongation of hospitalization, or persistent/significant disability. AE grades: mild (1), moderate (2), severe (3), life-threatening (4), death (5). ALT flare= \>2x baseline \& \>10x ULN up to end of therapy + 5 days. Hepatic SAE=SAEs consistent with worsening of hepatitis or hepatic decompensation.

    Time frame: cumulative through the end of on-treatment observation as available at the time of the Week 48 dataset

  9. Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs

    Laboratory abnormalities reported as clinical AEs

    Time frame: Week 48

08

Results

Posted Jan 6, 2010

Participant flow

Participant flow — Overall Study
MilestoneEntecavirAdefovir
Started3534
As-randomized population3534
As-treated population3633
Completed3333
Not completed21
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01
Withdrew: Relocated10

Outcome measures

PrimaryChange From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12

Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 12, adjusted for baseline (Week 12 - baseline). A negative value = improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · log10 copies/mL
Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12
log10 copies/mLEntecavirAdefovir
Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12-6.23 ± 0.247-4.52 ± 0.357
SecondaryChange From Baseline in HBV DNA by PCR Assay at Week 48

Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 48, adjusted for baseline (Week 48 - Baseline). A negative value = improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · log10 c/mL
Change From Baseline in HBV DNA by PCR Assay at Week 48
log10 c/mLEntecavirAdefovir
Change From Baseline in HBV DNA by PCR Assay at Week 48-7.28 ± 0.327-5.08 ± 0.455
SecondaryViral Load Undetectable (HBV DNA <300 Copies/mL)

Number of Subjects with HBV DNA \<300 copies/mL by Roche COBAS® Amplicor (limit of quantitation 300 copies/mL)

Time frame:
Week 48
Reported as:
Number · Participants
Viral Load Undetectable (HBV DNA <300 Copies/mL)
ParticipantsEntecavirAdefovir
Viral Load Undetectable (HBV DNA <300 Copies/mL)196
SecondaryAlanine Aminotransferase (ALT) Normalization

Number of participants with ALT ≤ 1 x upper limit of normal (ULN)

Time frame:
Week 48
Reported as:
Number · participants
Alanine Aminotransferase (ALT) Normalization
participantsEntecavirAdefovir
Alanine Aminotransferase (ALT) Normalization2520
SecondaryHBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε) and effectiveness of the study treatment in blocking de novo infection of susceptible cells (η). The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.

Time frame:
Week 12
Reported as:
Number · percent effective
HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections
percent effectiveEntecavirAdefovir
Efficacy in blocking virus production - ε99.8799.46
Effectiveness in blocking de novo infections - η6.075.87
SecondaryHBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the clearance rate of the free virus (c), the death rate of productively infected cells (δ), The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.

Time frame:
Week 12
Reported as:
Number · per day
HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate
per dayEntecavirAdefovir
Viral Clearance - c1.700.91
Infected cell death - δ0.080.04
SecondaryHBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus

The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. An important derived parameter is the half-life of free virus (ie, the average amount of time for HBV particles in plasma to be reduced to half the initial level), calculated as 24\*ln(2)/c. The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.

Time frame:
Week 12
Reported as:
Number · hours
HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus
hoursEntecavirAdefovir
HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus14.5232.46
SecondaryHBV DNA Viral Kinetics - Spline Model

This analysis uses a 3-parameter piece-wise linear model and describes the biphasic decline in HBV DNA (measured by PCR assay) through Week 12. The 3 parameters are the values for the 2 slopes, describing the first and second phase declines, respectively, and the estimated HBV DNA at the knot (at day 10; the time point where the 2 phases join). The biphasic viral decay kinetics for each treatment were obtained using a spline fitting procedure to estimate the 3 parameters for each subject; these estimates were then averaged within each treatment group.

Time frame:
Week 12
Reported as:
Number · log10 copies/mL
HBV DNA Viral Kinetics - Spline Model
log10 copies/mLEntecavirAdefovir
First slope (first phase of viral decay)-0.391-0.329
Second slope (second phase of viral decay)-0.034-0.024
SecondarySummary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths

AE=new untoward medical occurrence or worsening of pre-existing medical condition regardless of causal relationship to treatment. SAE=untoward medical occurrence that is life-threatening, a congenital anomaly/birth defect, or an important medical event, or results in death, inpatient hospitalization/prolongation of hospitalization, or persistent/significant disability. AE grades: mild (1), moderate (2), severe (3), life-threatening (4), death (5). ALT flare= \>2x baseline \& \>10x ULN up to end of therapy + 5 days. Hepatic SAE=SAEs consistent with worsening of hepatitis or hepatic decompensation.

Time frame:
cumulative through the end of on-treatment observation as available at the time of the Week 48 dataset
Reported as:
Number · Participants
Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths
ParticipantsEntecavirAdefovir
Death00
Serious AE13
Discontinuation due to AE01
Malignant neoplasm00
On Treatment: Any AE2827
On Treatment: Headache96
On Treatment: Upper Respiratory Infection88
On Treatment: Influenza64
On Treatment: Nasopharyngitis46
On Treatment: Pyrexia46
On Treatment: Back Pain05
On Treatment: Grade 3-4 AEs25
ALT Flare01
Hepatic SAE12
SecondarySummary of Safety - Laboratory Abnormalities Reported as Clinical AEs

Laboratory abnormalities reported as clinical AEs

Time frame:
Week 48
Reported as:
Number · Participants
Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs
ParticipantsEntecavirAdefovir
ALT increased12
Lipase increased12
Blood phosphorus decreased01
Liver function test abnormal01
Platelet count decreased01
Protein urine present01

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADV 10 mg—2/33 (6.1%)16/33 (48.5%)
ETV 0.5 mg—1/36 (2.8%)17/36 (47.2%)
Most frequent serious events
Most frequent serious events
EventADV 10 mgETV 0.5 mg
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/331/36
RIB FRACTUREInjury, poisoning and procedural complications1/330/36
Most frequent other events
Showing 10 of 11
Most frequent other events
EventADV 10 mgETV 0.5 mg
HEADACHENervous system disorders5/338/36
COUGHRespiratory, thoracic and mediastinal disorders4/332/36
INFLUENZAInfections and infestations2/334/36
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/334/36
LIPASE INCREASEDInvestigations2/330/36
DIZZINESSNervous system disorders2/330/36
NASOPHARYNGITISInfections and infestations2/332/36
BACK PAINMusculoskeletal and connective tissue disorders2/330/36
RHINORRHOEARespiratory, thoracic and mediastinal disorders2/330/36
MALAISEGeneral disorders2/330/36

Baseline characteristics

Age Continuous
Age Continuous(years)EntecavirAdefovirTotal
Mean37 ± 2.332 ± 1.934 ± 1.5
Age Continuous
Age Continuous(participants)EntecavirAdefovirTotal
Median38 (18 to 76)28 (17 to 57)31 (17 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)EntecavirAdefovirTotal
Female131124
Male222345
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EntecavirAdefovirTotal
Asian313061
Native Hawaiian or Other Pacific Islander011
Black or African American325
White112
Region of Enrollment
Region of Enrollment(participants)EntecavirAdefovirTotal
North America91322
East Asia262147
Prior interferon (IFN)
Prior interferon (IFN)(Participants)EntecavirAdefovirTotal
Prior IFN112
No prior IFN343367
Alanine Aminotransferease (ALT)
Alanine Aminotransferease (ALT)(U/L)EntecavirAdefovirTotal
Mean109.4 ± 81.76176.4 ± 207.22142.4 ± 159.12
Hepatitis B virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR)
Hepatitis B virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR)(log10 copies/mL)EntecavirAdefovirTotal
Mean10.45 ± 2.1259.89 ± 1.20110.18 ± 1.742
09

Study locations

24 sites
  • Local Institution
    San Diego, California, United States
  • Local Institution
    San Francisco, California, United States
  • Local Institution
    Torrance, California, United States
  • Local Institution
    Miami, Florida, United States
  • Local Institution
    North Miami Beach, Florida, United States
  • Local Institution
    Baltimore, Maryland, United States
  • Local Insitution
    New York, New York, United States
  • Local Institution
    New York, New York, United States
  • Local Institution
    Philadelphia, Pennsylvania, United States
  • Local Institution
    Dallas, Texas, United States
  • Local Institution
    Galveston, Texas, United States
  • Local Institution
    Edmonton, Alberta, Canada
  • Local Institution
    Vancouver, British Columbia, Canada
  • Local Institution
    Toronto, Ontario, Canada
  • Local Institution
    Chai Wan, Hong Kong
  • Local Institution
    Pokfulham, Hong Kong
  • Local Institution
    Tai Po, Hong Kong
  • Local Institution
    Jakarta, Indonesia
  • Local Institution
    Cebu, Philippines
  • Local Institution
    Manila, Philippines
  • Local Institution
    Singapore, Singapore
  • Local Institution
    Taichung, Taiwan
  • Local Institution
    Taoyan, Taiwan
  • Local Institution
    Bankok, Thailand
10

References and documents

Publications

  • Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009 Jan;49(1):72-9. doi: 10.1002/hep.22658. PubMed 19065670 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jan 2006 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2004
First posted
Nov 16, 2004
Start
Dec 2004
Primary completionActual
Jan 2006
CompletionActual
Apr 2008
Results first posted
Jan 6, 2010
Last update
Aug 10, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00096785
First posted
Nov 16, 2004
Start date
Dec 2004
Primary completion
Jan 2006
Completion
Apr 2008
Results posted
Jan 6, 2010
Last update
Aug 10, 2010

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Entecavir · Adefovir

Start the discussion